Longbio Pharma (Suzhou) Co (HKSE:01779) OCF Margin %: 0.00% (As of Dec. 2025)


HKSE:01779 Longbio Pharma (Suzhou) Co Ltd HKSE:01779
10 GF Score
Price HK$157.20
View Full Analysis

What is Longbio Pharma (Suzhou) Co OCF Margin %?

Longbio Pharma (Suzhou) Co HKSE:01779 +3.63% 10 OCF Margin % is 0.00% as of Dec. 2025. GuruFocus rates HKSE:01779 with a GF Score™ of 10/100. Among 960 Biotechnology companies, Longbio Pharma (Suzhou) Co ranks worse than 104166.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Longbio Pharma (Suzhou) Co's Cash Flow from Operations for the six months ended in Dec. 2025 was HK$-133.72 Mil. Longbio Pharma (Suzhou) Co's Revenue for the six months ended in Dec. 2025 was HK$0.00 Mil. Therefore, Longbio Pharma (Suzhou) Co's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Longbio Pharma (Suzhou) Co's current OCF Yield % is -1.15%.

The historical rank and industry rank for Longbio Pharma (Suzhou) Co's OCF Margin % or its related term are showing as below:


HKSE:01779's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Longbio Pharma (Suzhou) Co OCF Margin % Related Terms

Longbio Pharma (Suzhou) Co OCF Margin % Historical Data

* Premium members only.

The historical data trend for Longbio Pharma (Suzhou) Co's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longbio Pharma (Suzhou) Co OCF Margin % Chart

Longbio Pharma (Suzhou) Co Annual Data
Trend Dec24 Dec25
OCF Margin %
0.00 0.00

Longbio Pharma (Suzhou) Co Semi-Annual Data
Dec24 Dec25
OCF Margin % 0.00 0.00
HKSE:01779
10GF Score
Longbio Pharma (Suzhou) Co Ltd HKSE:01779
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Longbio Pharma (Suzhou) Co OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Longbio Pharma (Suzhou) Co's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-133.715/0
= %

Longbio Pharma (Suzhou) Co's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-133.715/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Longbio Pharma (Suzhou) Co (HKSE:01779) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Longbio Pharma (Suzhou) Co and its competitors. According to the industry distribution chart, Longbio Pharma (Suzhou) Co ranks #999999 out of 960 companies in the Biotechnology industry.
Is Longbio Pharma (Suzhou) Co's OCF Margin % too high?
Longbio Pharma (Suzhou) Co's current OCF Margin % is 0.00%. Based on the distribution chart, Longbio Pharma (Suzhou) Co ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Longbio Pharma (Suzhou) Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Longbio Pharma (Suzhou) Co's OCF Margin % compare to ?
According to the Biotechnology industry distribution chart, Longbio Pharma (Suzhou) Co ranks #999999 out of 960 companies for OCF Margin %. This places Longbio Pharma (Suzhou) Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Longbio Pharma (Suzhou) Co and its competitors. Longbio Pharma (Suzhou) Co's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longbio Pharma (Suzhou) Co stock overvalued right now?
Longbio Pharma (Suzhou) Co (HKSE:01779) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Longbio Pharma (Suzhou) Co's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Longbio Pharma (Suzhou) Co (HKSE:01779), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Longbio Pharma (Suzhou) Co Business Description

Comparable Companies
Address No. 128 Yinhe Road, Dongnan Subdistrict, 5th Floor, Building F, Area A, Changshu City, Jiangsu Province, Suzhou, CHN
Longbio Pharma (Suzhou) Co Ltd is a clinical-stage biotechnology company. The company and its subsidiaries are principally engaged in the research, development, manufacture and commercialisation of pharmaceutical products in the People's Republic of China (the PRC). It has developed a comprehensive product pipeline for biologic treatments targeting rhinology, dermatology, respiratory, hematology, nephrology and other autoimmune diseases, targeting allergic and autoimmune diseases. Its pipeline includes LP-003, LP-00A, LP-005, LP-00C, and LP-00D.
10GF Score

Get the complete analysis for HKSE:01779

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$157.20
Price